Girón BJA, Fernández GA, Trujillo FY, Ramos LN, Silva DO

Language: Spanish
References: 15
Page: 2096-3000
PDF size: 62.93 Kb.

ABSTRACT

A descriptive and cross-sectional study of 50 prediabetic patients, belonging to "Ernesto Guevara de la Serna" Polyclinic, Boniato town in Santiago de Cuba was carried out from January to December, 2012, with the aim of characterizing some clinical and epidemiological aspects of prediabetes. The percentage was used as summary measure. The female sex and the age groups 40-49, 50-59 years prevailed in the series. Among the most frequent risk factors there were: obesity and overweight, hypertension and first degree family pathological history of consanguinity for diabetes mellitus. Intolerance to glucose was the diagnostic category with the higher contribution of cases for this disorder, where as, the comorbidity found in order of frequency corresponded to hypertension (50.0%) and to ischemic cardiopathy (26.0%).

REFERENCES

1. Valdés S, Delgado E. Epidemiología de la prediabetes en España. Av Diabetol. 2009;25(2):99-104.

2. US Department of Health and Human Services, American Diabetes Association. HHS, ADA warns Americans of “pre-diabetes”, encourage people to take healthy steps to reduce risks. Washington, DC: DHHS;2002 [citado 8 Ene 2009].

3. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50.

4. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9549):1770.

5. Villanueva V. Complicaciones agudas de la diabetes mellitus. Rev de postgrado de la VI Cátedra de Medicina. 2003;130:19-24.

6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-S69.

7. Artola Menéndez S. Prevención de la diabetes tipo 2 basada en la terapia nutricional y/o el aumento de la actividad física. Av Diabetol. 2009;25(2):110-6.

8. Blonde L, Warren-Boulton E. Traducir la ciencia a la práctica: el Programa Nacional de Educación Diabética de EEUU. Diabetes Voice. 2007;52(1): 20-3.

9. González Suárez RM, Perich Amador P, Arranz Calzado C. Heterogeneidad de los trastornos metabólicos de las etapas iniciales de la diabetes mellitus 2. Rev Cubana Endocrinol. 2009[citado 4 May 2012];20(1).

10. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822.

11. Malacara JM, Garay Sevilla ME. Los conceptos en evolución sobre diabetes. Acta universitaria. 2009;19(2):5-10.

12. Mendoza Beltrán F. Síndrome metabólico, tratamiento y riesgo de diabetes mellitus. Acta Neurol Colombia. 2007;23(2):77-89.

13. Vigil Medina L, López Jiménez M, García Carretero R. Recomendaciones específicas para el manejo del paciente con síndrome metabólico. Hipertensión. 2007;24(3):101-9.

14. American Diabetes Asociation. Standards of medical care in diabetes. Diabetes Care. Actualización Médica Periódica.2009;32(suppl 1):S13-S61.

15. Modrego Navarro A, Rodríguez Ledo MP, Cucalón Arenal JM, Tarraga López PJ, Robledo del Corro M, Montilla Grazón L. Impacto de la prediabetes y el sexo en el riesgo cardiovascular asociado al síndrome metabólico. Hipertensión. 2010;27(1):4-12.